<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myopathies affecting the extraocular muscles in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myopathies affecting the extraocular muscles in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myopathies affecting the extraocular muscles in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew G Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul W Brazis, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Evelyn A Paysse, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Most generalized myopathies do not affect the extraocular muscles. However, there are some notable exceptions. Chronic progressive external ophthalmoplegia (CPEO) is a nonspecific term that is used to describe a range of myopathies that affect the extraocular muscles. These progressive ophthalmoplegias include:</p><p class="bulletIndent1"><span class="glyph">●</span>Isolated CPEO</p><p class="bulletIndent1"><span class="glyph">●</span>Kearns-Sayre syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Oculopharyngeal muscular dystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Myotonic dystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Myotubular myopathy</p><p></p><p>The progressive forms of ophthalmoplegia should be distinguished from the static forms of ophthalmoplegia, which include:</p><p class="bulletIndent1"><span class="glyph">●</span>Agenesis of extraocular muscles</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital fibrosis syndromes (see  <a class="medical medical_review" href="/z/d/html/6266.html" rel="external">"Causes of vertical strabismus in children", section on 'Congenital fibrosis of the extraocular muscles'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital myopathies (eg, centronuclear myopathy, central core myopathy, multicore myopathy) (see  <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">"Congenital myopathies"</a>)</p><p></p><p>The extraocular muscles often are involved in the mitochondrial myopathies, such as Kearns-Sayre syndrome [<a href="#rid1">1</a>]. Mitochondrial myopathies also can manifest with facial, bulbar, and limb myopathy; neurologic findings (eg, ataxia, spasticity, peripheral neuropathy, deafness, dementia); other ocular findings (eg, optic atrophy, pigmentary degeneration of retina); cardiac conduction abnormalities; gastrointestinal motility; and endocrine, skin, and skeletal abnormalities. (See  <a class="medical medical_review" href="/z/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a>.)</p><p>Other ocular myopathies beyond the scope of this review are associated with generalized muscle involvement (eg, proximal or distal limb muscle involvement) or neurodegenerative diseases (eg, spinocerebellar degeneration, Werdnig-Hoffmann syndrome). (See  <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">"Congenital myopathies"</a> and  <a class="medical medical_review" href="/z/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a> and  <a class="medical medical_review" href="/z/d/html/6146.html" rel="external">"Spinal muscular atrophy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H13933981"><span class="h2">Chronic progressive external ophthalmoplegia</span><span class="headingEndMark"> — </span>Patients with chronic progressive external ophthalmoplegia (CPEO) usually present with a painless, slowly progressive (and sometimes asymptomatic) ophthalmoplegia. The ocular motility defect is typically bilateral and symmetric, and for this reason few patients complain of diplopia, even if they have dramatic or complete ophthalmoplegia. Patients also have bilateral ptosis of variable severity. The pupil is spared (external ophthalmoplegia). In addition, optic atrophy and retinal pigmentary degeneration may be present in some patients, particularly those who have mitochondrial disorders. The clinical course usually is sufficient to make the diagnosis and exclude alternative etiologies, such as myasthenia gravis.</p><p>During childhood, CPEO may be isolated or occur in conjunction with other myopathies, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Kearns-Sayre syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Oculopharyngeal muscular dystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Myotonic dystrophy</p><p class="bulletIndent1"><span class="glyph">●</span>Myotubular myopathy</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Kearns-Sayre syndrome</span><span class="headingEndMark"> — </span>Kearns-Sayre syndrome is a mitochondrial cytopathy that is characterized by CPEO, retinal pigmentary changes, and heart block. Patients are typically normal at birth. Progressive ophthalmoplegia usually develops between 5 and 20 years of age, although it may occur earlier. Most cases are sporadic.</p><p>The ocular findings include bilateral and symmetric involvement of the horizontal and vertical muscles, bilateral ptosis, and normal pupils. An atypical pigmentary retinopathy ("salt and pepper") may be present; some patients have a corneal opacity. The ophthalmoplegia progresses slowly over many years and is often asymptomatic because it is insidious and bilaterally symmetric. As the extraocular myopathy progresses, generalized muscle weakness and other systemic manifestations may occur.</p><p>Nonocular manifestations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac – Heart block, sometimes even sudden death (may require monitoring with sequential electrocardiograms or treatment with a pacemaker) [<a href="#rid2">2,3</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic – Deafness and vestibular dysfunction, cerebellar ataxia, corticospinal dysfunction, electroencephalogram abnormalities, elevated cerebrospinal fluid protein (&gt;100 mg/dL), or widespread muscular dystrophy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endocrine and metabolic – Short stature, gonadal failure, diabetes mellitus, thyroid disease, hyperaldosteronism; hypomagnesemia; and bone, tooth, and calcification abnormalities [<a href="#rid4">4,5</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal – Renal tubular involvement is rare [<a href="#rid4">4,5</a>]</p><p></p><p>Laboratory findings may include elevated plasma lactate and pyruvate concentrations. Skeletal or ocular muscle biopsy demonstrates defects in the mitochondrial respiratory chain and "ragged red fibers" histologically.</p><p class="headingAnchor" id="H4"><span class="h2">Oculopharyngeal muscular dystrophy</span><span class="headingEndMark"> — </span>Oculopharyngeal muscular dystrophy is another type of CPEO that usually has onset at approximately 40 years of age, although earlier onset may occur [<a href="#rid6">6,7</a>]. Most patients have a common ancestor from Quebec. In the French-Canadian population, oculopharyngeal muscular dystrophy usually follows an autosomal-dominant inheritance pattern with 100 percent penetrance [<a href="#rid2">2</a>]. However, autosomal-recessive and sporadic forms occur in other ethnic groups. (See  <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">"Oculopharyngeal, distal, and congenital muscular dystrophies"</a>.)</p><p>Characteristic features include difficulty with swallowing, more prominent ptosis than extraocular muscle involvement, weakness of the orbicularis muscle, and cytoplasmic inclusions on muscle biopsy [<a href="#rid6">6</a>]. The diagnosis is usually made by the family history and clinical presentation.</p><p class="headingAnchor" id="H5"><span class="h2">Myotonic dystrophy</span><span class="headingEndMark"> — </span>Myotonic dystrophy, another systemic myopathy that affects the extraocular muscles, has two forms: congenital and classical. The congenital form occurs in infants born to mothers with myotonic dystrophy. The infants present with profound hypotonia, facial diplegia, feeding problems, respiratory difficulties, and skeletal deformities, such as clubfeet. (See  <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis"</a>.)</p><p>The classical form of the disease has onset in adolescence or adulthood. Ocular findings include orbicularis weakness; myotonia on lid closure; ptosis; poor eccentric gaze holding; slow saccades; sluggish, miotic pupils; blepharitis; dry-eye syndrome; low intraocular pressure (hypotony); lens changes (eg, polychromatic cataracts, posterior cortex star, posterior subcapsular cataract); and pigmentary changes in macula. (See  <a class="medical medical_review" href="/z/d/html/6270.html" rel="external">"Cataract in children", section on 'Disease-associated'</a>.)</p><p>Nonocular findings include frontal baldness, testicular atrophy, cardiac abnormalities (eg, cardiomyopathy, conduction defects), narrow hatchet facies, and slack jaw.</p><p>The electromyography (EMG) demonstrates myopathic potentials and myotonia. Muscle histology may reveal internal nuclei, type I fiber atrophy, and ring fibers [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Myotubular myopathy</span><span class="headingEndMark"> — </span>Centronuclear myotubular myopathy is a rare X-linked congenital myopathy. Male infants have marked hypotonia and skeletal muscle weakness. Respiratory muscle impairment leads to respiratory failure. Facial weakness, ptosis, and extraocular muscle weakness typically occur, and impaired bulbar function contributes to feeding difficulty. Heterozygous female carriers may present with limb girdle and facial weakness. A more common form of the disorder occurs in both males and females and consists of relatively mild weakness and hypotonia that may be unrecognized in the neonatal period. Myotubular myopathy should be considered in the differential diagnosis of any infant who has hypotonia and either ptosis or ophthalmoplegia. (See  <a class="medical medical_review" href="/z/d/html/6148.html" rel="external">"Approach to the infant with hypotonia and weakness"</a> and  <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">"Congenital myopathies", section on 'Centronuclear (myotubular) myopathies'</a>.)</p><p>Similar clinical manifestations may be seen in neonatal or congenital myasthenia gravis [<a href="#rid9">9</a>], a disorder that must be excluded. Administration of an acetylcholinesterase inhibitor results in improvement in symptoms (eg, oxygenation, ventilation, or sucking) in infants with myasthenia gravis but not those with myotubular myopathy. (See  <a class="medical medical_review" href="/z/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants", section on 'Congenital myasthenic syndromes'</a>.)</p><p>Muscle biopsy in infants with myotubular myopathy demonstrates predominance of small type I fibers and centrally placed nuclei.</p><p class="headingAnchor" id="H7"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H13934003"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>In most cases, the diagnosis of chronic progressive external ophthalmoplegia (CPEO) can be made from the clinical course (painless, progressive, pupil-sparing ophthalmoplegia). Pain, pupil involvement, acute onset, fatigue, or fluctuating course suggest an alternate diagnosis  (<a class="graphic graphic_table graphicRef76783" href="/z/d/graphic/76783.html" rel="external">table 1</a>).</p><p>Examination of family members and a complete family history are important because the inheritance pattern can provide a clue to the underlying etiology. Myasthenia gravis should be excluded since a "chronic, fixed" myasthenia can mimic CPEO. (See  <a class="medical medical_review" href="/z/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis", section on 'Ocular function'</a>.)</p><p>Patients with CPEO should be evaluated by a neurologist and an ophthalmologist to exclude other disorders that mimic isolated CPEO, identify systemic diseases associated with CPEO (eg, mitochondrial disease), and evaluate for cardiac or other neurologic features of Kearns-Sayre syndrome.</p><p class="headingAnchor" id="H8"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>The laboratory evaluation of patients in whom a metabolic myopathy is being considered may include a number of tests  (<a class="graphic graphic_table graphicRef56365" href="/z/d/graphic/56365.html" rel="external">table 2</a>), not all of which are necessary in every patient. In patients in whom a mitochondrial disorder is being considered, serum and cerebrospinal lactate concentrations may be elevated, but this test is neither sensitive nor specific [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/6193.html" rel="external">"Approach to the metabolic myopathies", section on 'Evaluation and diagnosis'</a>.)</p><p>Muscle biopsy may be indicated for definitive diagnosis of Kearns-Sayre syndrome, myotonic dystrophy, or myotubular myopathy. Characteristic findings are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Kearns-Sayre syndrome – Ragged red fibers and evidence of cytochrome C oxidase deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Oculopharyngeal muscular dystrophy – Cytoplasmic inclusions [<a href="#rid6">6</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Myotonic dystrophy – Internal nuclei, type I fiber atrophy, and ring fibers [<a href="#rid8">8</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Myotubular myopathy – Predominance of small type I fibers and centrally placed nuclei</p><p></p><p>Electromyography (EMG) may be helpful in selected cases. Myopathic potentials and myotonia are present in myotonic dystrophy, but the EMG may not be diagnostic in early cases or in cases isolated to the extraocular muscles (isolated CPEO). EMG in other disorders may confirm evidence of myopathy but is not specific. EMG of the extraocular muscles is rarely performed except in institutions with research interests.</p><p>A number of mitochondrial mutations have been reported in patients with CPEO syndromes, and mitochondrial DNA studies may be helpful for diagnosis [<a href="#rid11">11-17</a>]. These tests are not universally available and usually require specialty laboratory testing.</p><p>Mutations in the DNA polymerase gamma, catalytic subunit (<em>POLG</em>) gene cause many of the inherited mitochondrial diseases in children and can produce a diverse group of phenotypes including autosomal-recessive progressive external ophthalmoplegia (arPEO) and autosomal-dominant progressive external ophthalmoplegia (adPEO) [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Radiologic evaluation</span><span class="headingEndMark"> — </span>The diagnosis of CPEO is usually made clinically. Neuroimaging studies are performed primarily to exclude alternative etiologies for ophthalmoplegia.</p><p>Cranial magnetic resonance imaging (MRI) in patients with CPEO may show signal abnormalities in the brainstem, brain, and thalami, and in extraocular muscle volume [<a href="#rid19">19,20</a>]. In one study, digitally measured extraocular muscle volume in subjects with CPEO was reduced compared with control subjects (215 mm<sup>3</sup> versus 366 mm<sup>3</sup> for the medial rectus, 202 mm<sup>3</sup> versus 365 mm<sup>3</sup> for the inferior rectus, and 269 mm<sup>3</sup> versus 425 mm<sup>3</sup> for the lateral rectus) [<a href="#rid20">20</a>]. This finding may help to distinguish CPEO from other conditions causing ophthalmoplegia. Magnetic resonance spectroscopy may show elevated lactate levels within regions of brain signal abnormalities in patients with Kearns-Sayre syndrome [<a href="#rid21">21</a>].</p><p>We recommend obtaining an MRI of the extraocular muscles in all patients with CPEO and magnetic resonance spectroscopy in selected patients (eg, those suspected to have Kearns-Sayre syndrome).</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Therapy for chronic progressive external ophthalmoplegia (CPEO) is supportive. Ptosis surgery can be performed in severely affected patients. However, extreme care must be taken to avoid overcorrection because of the risk of exposure keratopathy from the ophthalmoplegia and loss of Bell phenomenon [<a href="#rid22">22,23</a>]. Bell phenomenon is the rolling up of the eyes when the eyelids are closed; it typically occurs during sleep or with forced lid closure, but is lost in patients with CPEO. The loss of Bell phenomenon in conjunction with postoperative lagophthalmos (ie, incomplete eyelid closure) after correction of ptosis may result in corneal exposure, placing the patient at risk for exposure keratopathy.</p><p>Strabismus surgery can be performed to align the eyes, although it is not always necessary because involvement in CPEO tends to be bilateral and symmetric. The patients who do not require strabismus surgery tend to adapt to their ophthalmoplegia by turning their head or face to compensate for loss of gaze function. Such patients can be followed annually by the ophthalmologist. They may need special accommodations in school and may have activity restrictions, depending upon the presence and extent of associated myopathy. In addition:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have cardiac conduction defects should be referred to a cardiologist for evaluation and ongoing care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapies that have been tried, with variable success, in patients with mitochondrial cytopathies include the ketogenic diet [<a href="#rid24">24</a>], coenzyme Q [<a href="#rid21">21</a>], and <a class="drug drug_pediatric" data-topicid="13100" href="/z/d/drug information/13100.html" rel="external">bupivacaine</a> [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic progressive external ophthalmoplegia (CPEO) is a nonspecific term that is used to describe a range of myopathies that affect the extraocular muscles, including isolated CPEO, Kearns-Sayre syndrome, oculopharyngeal muscular dystrophy, and myotonic dystrophy. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CPEO usually present with a painless, slowly progressive (and sometimes asymptomatic) ophthalmoplegia. The ocular motility defect is typically bilateral and symmetric. They also have bilateral ptosis of variable severity, but the pupil is spared. Optic atrophy and retinal pigmentary degeneration may be present in some patients. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of CPEO usually can be made from the clinical course (painless, progressive, pupil-sparing ophthalmoplegia). Pain, pupil involvement, acute onset, fatigue, or fluctuating course suggest an alternate diagnosis  (<a class="graphic graphic_table graphicRef76783" href="/z/d/graphic/76783.html" rel="external">table 1</a>). Examination of family members and a complete family history can provide a clue to the underlying etiology. Myasthenia gravis should be excluded. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The laboratory evaluation of patients in whom a metabolic myopathy is being considered may include a number of tests  (<a class="graphic graphic_table graphicRef56365" href="/z/d/graphic/56365.html" rel="external">table 2</a>), not all of which are necessary in every patient. Muscle biopsy may be indicated for definitive diagnosis of Kearns-Sayre syndrome, myotonic dystrophy, or myotubular myopathy. Electromyography (EMG) may be helpful in selected cases. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Therapy for CPEO is supportive (eg, ptosis surgery, strabismus surgery, referral to cardiologist for patients with cardiac conduction defect). (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carta A, D'Adda T, Carrara F, Zeviani M. Ultrastructural analysis of extraocular muscle in chronic progressive external ophthalmoplegia. Arch Ophthalmol 2000; 118:1441.</a></li><li><a class="nounderline abstract_t">Barragán-Campos HM, Barrera-Ramírez CF, Iturralde Torres P, et al. Kearns-Sayre syndromes an absolute indication for prophylactic implantation of definitive pacemaker? Arch Inst Cardiol Mex 1999; 69:559.</a></li><li><a class="nounderline abstract_t">Fromenty B, Carrozzo R, Shanske S, Schon EA. High proportions of mtDNA duplications in patients with Kearns-Sayre syndrome occur in the heart. Am J Med Genet 1997; 71:443.</a></li><li><a class="nounderline abstract_t">Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome. Am J Nephrol 2001; 21:150.</a></li><li><a class="nounderline abstract_t">Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol (Oxf) 1992; 37:97.</a></li><li><a class="nounderline abstract_t">Hill ME, Creed GA, McMullan TF, et al. Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001; 124:522.</a></li><li><a class="nounderline abstract_t">Lacomis D, Kupsky WJ, Kuban KK, Specht LA. Childhood onset oculopharyngeal muscular dystrophy. Pediatr Neurol 1991; 7:382.</a></li><li class="breakAll">Dubowitz V. Muscle Biopsy: A Practical Approach, Bailliere Tindall, London 1985. p.380.</li><li><a class="nounderline abstract_t">Kim JH, Hwang JM, Hwang YS, et al. Childhood ocular myasthenia gravis. Ophthalmology 2003; 110:1458.</a></li><li><a class="nounderline abstract_t">Rose LV, Rose NT, Elder JE, et al. Ophthalmologic presentation of oxidative phosphorylation diseases of childhood. Pediatr Neurol 2008; 38:395.</a></li><li><a class="nounderline abstract_t">Campos Y, Gámez J, García A, et al. A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with ocular myopathy. Neuromuscul Disord 2001; 11:477.</a></li><li><a class="nounderline abstract_t">Ishikawa Y, Goto Y, Ishikawa Y, Minami R. Progression in a case of Kearns-Sayre syndrome. J Child Neurol 2000; 15:750.</a></li><li><a class="nounderline abstract_t">Marin-Garcia J, Goldenthal MJ, Sarnat HB. Kearns-Sayre syndrome with a novel mitochondrial DNA deletion. J Child Neurol 2000; 15:555.</a></li><li><a class="nounderline abstract_t">Saiwaki T, Shiga K, Fukuyama R, et al. A unique junctional palindromic sequence in mitochondrial DNA from a patient with progressive external ophthalmoplegia. Mol Pathol 2000; 53:333.</a></li><li><a class="nounderline abstract_t">Seneca S, Verhelst H, De Meirleir L, et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001; 58:1113.</a></li><li><a class="nounderline abstract_t">Spagnolo M, Tomelleri G, Vattemi G, et al. A new mutation in the mitochondrial tRNA(Ala) gene in a patient with ophthalmoplegia and dysphagia. Neuromuscul Disord 2001; 11:481.</a></li><li><a class="nounderline abstract_t">Van Goethem G, Dermaut B, Löfgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211.</a></li><li><a class="nounderline abstract_t">Wong LJ, Naviaux RK, Brunetti-Pierri N, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008; 29:E150.</a></li><li><a class="nounderline abstract_t">Marie SK, Carvalho AA, Fonseca LF, et al. Kearns-Sayre syndrome "plus". Classical clinical findings and dystonia. Arq Neuropsiquiatr 1999; 57:1017.</a></li><li><a class="nounderline abstract_t">Carlow TJ, Depper MH, Orrison WW Jr. MR of extraocular muscles in chronic progressive external ophthalmoplegia. AJNR Am J Neuroradiol 1998; 19:95.</a></li><li><a class="nounderline abstract_t">Choi C, Sunwoo IN, Kim HS, Kim DI. Transient improvement of pyruvate metabolism after coenzyme Q therapy in Kearns-Sayre syndrome: MRS study. Yonsei Med J 2000; 41:676.</a></li><li><a class="nounderline abstract_t">Daut PM, Steinemann TL, Westfall CT. Chronic exposure keratopathy complicating surgical correction of ptosis in patients with chronic progressive external ophthalmoplegia. Am J Ophthalmol 2000; 130:519.</a></li><li><a class="nounderline abstract_t">Wong VA, Beckingsale PS, Oley CA, Sullivan TJ. Management of myogenic ptosis. Ophthalmology 2002; 109:1023.</a></li><li><a class="nounderline abstract_t">Speeg-Schatz C, de Saint-Martin A, Christmann D. Congenital mitochondrial cytopathy and chronic progressive external ophthalmoplegia. Binocul Vis Strabismus Q 2001; 16:187.</a></li><li><a class="nounderline abstract_t">Andrews RM, Griffiths PG, Chinnery PF, Turnbull DM. Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Eye (Lond) 1999; 13 ( Pt 6):769.</a></li></ol></div><div id="topicVersionRevision">Topic 6271 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030833" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ultrastructural analysis of extraocular muscle in chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10742853" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Kearns-Sayre syndromes an absolute indication for prophylactic implantation of definitive pacemaker?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286453" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High proportions of mtDNA duplications in patients with Kearns-Sayre syndrome occur in the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11359024" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Severe hypomagnesemia and hypoparathyroidism in Kearns-Sayre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1424198" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endocrine dysfunction in Kearns-Sayre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11222452" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1764143" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Childhood onset oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1764143" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Childhood onset oculopharyngeal muscular dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867410" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Childhood ocular myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486820" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ophthalmologic presentation of oxidative phosphorylation diseases of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404120" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with ocular myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11108509" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Progression in a case of Kearns-Sayre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961796" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Kearns-Sayre syndrome with a novel mitochondrial DNA deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11193053" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A unique junctional palindromic sequence in mitochondrial DNA from a patient with progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448301" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404121" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A new mutation in the mitochondrial tRNA(Ala) gene in a patient with ophthalmoplegia and dysphagia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431686" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18546365" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10683696" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Kearns-Sayre syndrome "plus". Classical clinical findings and dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9432164" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : MR of extraocular muscles in chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079632" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transient improvement of pyruvate metabolism after coenzyme Q therapy in Kearns-Sayre syndrome: MRS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11024427" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chronic exposure keratopathy complicating surgical correction of ptosis in patients with chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986113" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of myogenic ptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11511285" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Congenital mitochondrial cytopathy and chronic progressive external ophthalmoplegia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707142" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
